Inactive Instrument

LogicBio Therapeutics, Inc.

LOGC

US54142F1021

LogicBio Therapeutics: Q3 Earnings Snapshot

November 14, 2022 at 08:08 am EST

LEXINGTON, Mass. (AP) _ LogicBio Therapeutics Inc. (LOGC) on Monday reported a loss of $5.8 million in its third quarter.

The Lexington, Massachusetts-based company said it had a loss of 18 cents per share.

The genome editing company posted revenue of $2.7 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LOGC at https://www.zacks.com/ap/LOGC

Latest news about LogicBio Therapeutics, Inc.

CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics	23-01-03	CI
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from S&P TMI Index	22-11-21	CI
LogicBio Therapeutics, Inc. Announces Management Changes	22-11-16	CI
AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics	22-11-16	MT
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index	22-11-16	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	22-11-14	CI
LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M	22-11-14	MT
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18	22-11-14	MT
LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement	22-10-07	CI
AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics	22-10-03	MT
ADRs End Higher, ABB and AstraZeneca Trade Actively	22-10-03	DJ
Sector Update: Health Care Stocks Catching Up With Broader Market Gains	22-10-03	MT
Sector Update: Health Care Stocks Mostly Higher in Afternoon Trading	22-10-03	MT
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar	22-10-03	MT
Sector Update: Health Care	22-10-03	MT
LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca	22-10-03	DJ
Sector Update: Health Care Stocks Edge Higher Premarket Monday	22-10-03	MT
Sector Update: Health Care	22-10-03	MT
ETF Preview: ETFs, Futures Advancing Pre-Bell Ahead of Manufacturing PMI Data	22-10-03	MT
AstraZeneca pays 660% premium for gene therapy firm LogicBio	22-10-03	RE
US Futures Higher to Kick Off Q4 Trading	22-10-03	MT
Top Premarket Gainers	22-10-03	MT
AstraZeneca to Buy LogicBio Therapeutics for $68 Million	22-10-03	DJ
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar	22-10-03	MT

Chart LogicBio Therapeutics, Inc.

Duration

Period

More charts

LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001, for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1 (HT1). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals